Myokardia Inc (NASDAQ:MYOK) insider Anastasios Gianakakos sold 4,000 shares of the business’s stock in a transaction on Friday, July 5th. The shares were sold at an average price of $49.73, for a total value of $198,920.00. Following the completion of the sale, the insider now owns 116,470 shares of the company’s stock, valued at $5,792,053.10. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.
NASDAQ:MYOK opened at $50.00 on Thursday. The firm’s fifty day moving average is $48.18. The company has a market cap of $2.32 billion, a P/E ratio of -28.41 and a beta of 2.07. Myokardia Inc has a fifty-two week low of $39.01 and a fifty-two week high of $67.79.
Myokardia (NASDAQ:MYOK) last released its earnings results on Thursday, May 9th. The biotechnology company reported ($0.93) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.28). Myokardia had a negative net margin of 201.81% and a negative return on equity of 19.98%. On average, sell-side analysts forecast that Myokardia Inc will post -3.75 earnings per share for the current fiscal year.
MYOK has been the subject of several recent research reports. Cantor Fitzgerald restated a “buy” rating and issued a $27.00 price target on shares of Spero Therapeutics in a research note on Thursday, May 9th. TheStreet upgraded TELUS from a “c+” rating to a “b-” rating in a research note on Thursday, April 4th. Zacks Investment Research downgraded ExlService from a “hold” rating to a “sell” rating in a research note on Wednesday. ValuEngine downgraded Zogenix from a “strong-buy” rating to a “buy” rating in a research note on Thursday, April 11th. Finally, JPMorgan Chase & Co. set a $90.00 price target on Duke Energy and gave the company a “hold” rating in a research note on Monday, May 20th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have given a buy rating to the company’s stock. Myokardia currently has a consensus rating of “Buy” and a consensus target price of $75.88.
Myokardia Company Profile
MyoKardia, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. Its lead product candidate is mavacamten, an orally administered small molecule, which is in Phase III clinical trial that is designed to reduce left ventricular contractility to alleviate the functional consequences and symptoms of obstructive hypertrophic cardiomyopathy (HCM) and prevent or reverse HCM progression, as well as in Phase II clinical trial for non-obstructive HCM.
Featured Story: Should You Consider an Index Fund?
Receive News & Ratings for Myokardia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myokardia and related companies with MarketBeat.com's FREE daily email newsletter.